Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion

Journal of Molecular and Cellular Cardiology

Volumn 43, Issue 2, 2007, Pages 130-136

  Toma, Catalin ^a   Letts, Dustin P ^a   Tanabe, Masaki ^a   Gorcsan III, John ^a   Counihan, Peter J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Erythropoietin; Fibrosis; Myocardial infarction; Remodeling

Indexed keywords

ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART VENTRICLE HYPERTROPHY; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; SWINE;

ANIMALS; CAPILLARIES; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; ERYTHROPOIETIN; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; RECEPTORS, ERYTHROPOIETIN; SWINE; VENTRICULAR REMODELING;

ANIMALIA; RODENTIA; SUS; SUS SCROFA DOMESTICA;

EID: 34447513916     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2007.05.014     Document Type: Article

References (29)

1. Beltrami C.A., Finato N., Rocco M., Feruglio G.A., Puricelli C., Cigola E., et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 89 1 (1994) 151-163
2. Zimmerman S.D., Criscione J., and Covell J.W. Remodelling in the myocardium adjacent to an infarction in a pig left ventricle. Am. J. Physiol. 287 (2004) H2697-H2704
3. Kloner R.A., and Rezkalla S.H. Cardiac protection during acute myocardial infarction: where do we stand in 2004?. J. Am. Coll. Cardiol. 44 2 (2004) 276-286
4. Maiese K., Li F., and Chong Z.Z. New avenues of exploration for erythropoietin. JAMA 293 1 (2005) 90-95
5. Calvillo L., Latini R., Kajstura J., Leri A., Anversa P., Ghezzi P., et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl. Acad. Sci. U. S. A. 100 8 (2003) 4802-4806
6. Parsa C.J., Matsumoto A., Kim J., Riel R.U., Pascal L.S., Walton G.B., et al. A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 112 7 (2003) 999-1007
7. Miki T, Miura T, Tanno M, Nishihara M, Naitoh K, Sato T, et al. Impairment of cardioprotective PI3K-Akt signaling by post-infarct ventricular remodeling is compensated by an ERK-mediated pathway. Basic Res Cardiol 2007;120:163-70.
8. Bahlmann F.H., DeGroot K., Duckert T., Niemczyk E., Bahlmann E., Boehm S.M., et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 64 5 (2003) 1648-1652
9. Rui T., Feng Q., Lei M., Peng T., Zhang J., Xu M., et al. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc. Res. 65 (2005) 719-727
10. Moon C., Krawczyk M., Ahn D., Ahmet I., Paik D., Lakatta E.G., et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. PNAS 100 20 (2003) 11612-11617
11. Nishiya D., Omura T., Shimada K., Matsumoto R., Kusuyama T., Enomoto S., et al. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J. Pharmacol. Sci. 101 1 (2006) 31-39
12. Gao E, Boucher M, Chuprun JK, Zhou R, Eckhart A, Koch WJ. Darbepoetin alpha, a long-acting erythropoietin analogue, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol (in press).
13. Kritensen J., Maeng M., Rehling M., Berg J.S., Mortensen U.M., Nielsen S.S., et al. Lack of acute cardioprotective effect from preischemic erythropoietin administration in a porcine coronary occlusion model. Clin. Physiol. Funct. Imaging 25 (2005) 305-310
14. Olea F.D., Vera Janavel G., De Lorenzi A., Cuniberti L., Yannarelli G., Cabeza Meckert P., et al. High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction. J. Cardiovasc. Pharmacol. 47 (2006) 736-741
15. Dohi K., Pinsky M.R., Kanzaki H., Severyn D., and Gorcsan III J. Effects of radial left ventricular dyssynchrony on cardiac performance using quantitative tissue Doppler radial strain imaging. J. Am. Soc. Echocardiogr. 19 5 (2006) 475-482
16. Matre K., Fannelop T., Dahle G.O., Heimdal A., and Grong K. Radial strain gradient across the normal myocardial wall in open-chest pigs measured with Doppler strain rate imaging. J. Am. Soc. Echocardiogr. 18 10 (2005) 1066-1073
17. Hirata A., Minamino T., Asanuma H., Fujita M., Wakeno M., Myoishi M., et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J. Am. Coll. Cardiol. 48 1 (2006) 176-184
18. Lipsic E., van der Meer P., Voors A.A., Westenbrink B.D., van den Heuvel A.F., de Boer H.C., et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc. Drugs Ther. 20 2 (2006) 135-141
19. Krause K.T., Jaquet K., Geidel S., Schneider C., Mandel C., Stoll H.P., et al. Percutaneous endocardial injection of erythropoietin: assessment of cardioprotection by electromechanical mapping. Eur. J. Heart Fail. 8 5 (2006) 443-450
20. Li L., Takemura G., Li Y., Miyata S., Esaki M., Okada H., et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 113 4 (2006) 535-543
21. Parsa C.J., Kim J., Riel R.U., Pascal L.S., Thompson R.B., Petrofski J.A., et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J. Biol. Chem. 279 20 (2004) 20655-20662
22. Jaquet K., Krause K., Tawakol-Khodai M., Geidel S., and Kuck K.H. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc. Res. 64 2 (2002) 326-333
23. Chong Z.Z., Kang J.Q., and Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 106 23 (2002) 2973-2979
24. Van der Meer P., Lipsic E., Henning R.H., Boddeus K., van der Velden J., Voors A.A., et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J. Am. Coll. Cardiol. 46 1 (2005 (Jul 5)) 125-133
25. Rissanen T.T., Markkanen J.E., Gruchala M., Heikura T., Puranen A., Kettunen M.I., et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ. Res. 92 10 (2003 (May 30)) 1098-1106
26. Elliott S., Busse L., Bass M.B., Lu H., Sarosi I., Sinclair A.M., et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107 5 (2006 (Mar 1)) 1892-1895
27. Depping R., Kawakami K., Ocker H., Wagner J.M., Heringlake M., Noetzold A., et al. Expression of the erythropoietin receptor in the human heart. J. Thorac. Cardiovasc. Surg. 130 3 (2005) 877-878
28. Weidemann F., Jamal F., Kowalski M., Kukulski T., D'Hooge J., Bijnens B., et al. Can strain rate and strain quantify changes in regional systolic function during dobutamine infusion, B-blockade, and atrial pacing-implications for quantitative stress echocardiography. J. Am. Soc. Echocardiogr. 15 5 (2002) 416-424
29. Marwick T.H. Measurement of strain and strain rate by echocardiography: ready for prime time?. J. Am. Coll. Cardiol. 47 7 (2006) 1313-1327